Risk of requiring a wheelchair in primary progressive multiple sclerosis : Data from the ORATORIO trial and the MSBase registry
Montalban, Xavier (Hospital Universitari Vall d'Hebron)
Butzkueven, Helmut (Monash University)
Spelman, Tim (University of Melbourne)
Horakova, Dana (Charles University. Faculty of Medicine in Hradec Králové)
Hughes, Stella (Craigavon Area Hospital)
Solaro, Claudio Marcello (CRRF "Mons. Luigi Novarese")
Izquierdo, Guillermo (Hospital Vithas Nisa)
Kubala Havrdova, Eva (Charles University)
Grand'Maison, Francois (Neuro Rive-Sud)
Prat, Alexandre (Universite de Montreal)
Girard, Marc (Universite de Montreal)
Hupperts, Raymond (Zuyderland Ziekenhuis)
Onofrj, Marco (University G. d'Annunzio)
Lugaresi, Alessandra (UOSI Riabilitazione Sclerosi Multipla)
Taylor, Bruce (Royal Hobart Hospital)
Giovannoni, Gavin (Queen Mary University of London)
Kappos, Ludwig (University of Basel)
Hauser, Stephen L. (University of California)
Craveiro, Licinio (F. Hoffmann-La Roche Ltd)
Freitas, Rita (F. Hoffmann-La Roche Ltd)
Model, Fabian (F. Hoffmann-La Roche Ltd)
Overell, James (F. Hoffmann-La Roche Ltd)
Muros-Le Rouzic, Erwan (F. Hoffmann-La Roche Ltd)
Sauter, Annette (F. Hoffmann-La Roche Ltd)
Wang, Qing (F. Hoffmann-La Roche Ltd)
Wormser, David (F. Hoffmann-La Roche Ltd)
Wolinsky, Jerry S. (McGovern Medical School at UTHealth (Houston, Estats Units d'Amèrica))
MSBase Study Group
Universitat Autònoma de Barcelona

Data:	2022
Descripció:	9 pàg.
Resum:	Background and purpose: Reaching Expanded Disability Status Scale (EDSS) ≥7. 0 represents the requirement for a wheelchair. Here we (i) assess the effect of ocrelizumab on time to EDSS ≥7. 0 over the ORATORIO (NCT01194570) double-blind and extended controlled periods (DBP+ECP), (ii) quantify likely long-term benefits by extrapolating results, and (iii) assess the plausibility of extrapolations using an independent real-world cohort (MSBase registry; ACTRN12605000455662). Methods: Post hoc analyses assessing time to 24-week confirmed EDSS ≥7. 0 in two cohorts of patients with primary progressive multiple sclerosis (baseline EDSS 3. 0-6. 5) were investigated in ORATORIO and MSBase. Results: In the ORATORIO DBP+ECP, ocrelizumab reduced the risk of 24-week confirmed EDSS ≥7. 0 (hazard ratio = 0. 54, 95% confidence interval [CI]: 0. 31-0. 92; p = 0. 022). Extrapolated median time to 24-week confirmed EDSS ≥7. 0 was 12. 1 and 19. 2 years for placebo and ocrelizumab, respectively (7. 1-year delay [95% CI: -4. 3 to 18. 4]. In MSBase, the median time to 24-week confirmed EDSS ≥7. 0 was 12. 4 years. Conclusions: Compared with placebo, ocrelizumab significantly delayed time to 24-week confirmed wheelchair requirement in ORATORIO. The plausibility of the extrapolated median time to reach this milestone in the placebo group was supported by observed real-world data from MSBase. Extrapolated benefits for ocrelizumab over placebo could represent a truly meaningful delay in loss of ambulation and independence.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Disease progression ; Ocrelizumab ; Primary progressive multiple sclerosis ; Wheelchair
Publicat a:	European Journal of Neurology, Vol. 29 Núm. 4 (2022) , p. 1082-1090, ISSN 1468-1331

DOI: 10.1111/ene.14824
PMID: 33724638

9 p, 341.7 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats